EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Resmetirom: The First Disease‐Specific Treatment for MASH

Ali Mohamed Mousa iD, Mervat Mahmoud iD, Ghaida Mubarak AlShuraiaan iD

International Journal of Endocrinology · 2025-01 · 2025 (1)

DOI: 10.1155/ije/6430023 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Endocrinology, online erschienen am 26.02.2025. Verfasst von Ali Mohamed Mousa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Family Medicine Department, Ahmadi Hospital, Kuwait Petroleum Corporation, Al Ahmadi, Kuwait. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2023, the medical terminology for Nonalcoholic Fatty Liver Disease (NAFLD) and NA SteatoHepatitis (NASH) was updated to Metabolic Dysfunction‐Associated SteatoticLiver Disease (MASLD) and MA SteatoHepatitis (MASH). This review highlights the critical epidemiological, pathophysiological, and therapeutic aspects of MASH, focusing on the novel treatment option, resmetirom. Resmetirom, a thyroid hormone receptor‐beta (THR‐β) agonist, specifically targets liver function to simulate localized hyperthyroidism, effectively reducing lipid accumulation and liver fibrosis without the systemic effects commonly associated with thyroid hormone therapy. Clinical trials, particularly the pivotal MAESTRO‐NASH trial, have demonstrated significant improvements in liver health metrics, achieving primary endpoints by resolving MASH without worsening fibrosis and showing a favorable safety profile. This paper reviews the mechanism of action, efficacy, and safety of resmetirom, providing insight into its potential to change the therapeutic landscape for patients suffering from MASH.

Autor:innen und Institutionen

  • Family Medicine Department, Ahmadi Hospital, Kuwait Petroleum Corporation, Al Ahmadi, Kuwait.

ORCID-Profile: Ali Mohamed Mousa, Mervat Mahmoud, Ghaida Mubarak AlShuraiaan

Zitieren

APA

Mousa, A. M., Mahmoud, M., & AlShuraiaan, G. M. (2025). Resmetirom: The First Disease‐Specific Treatment for MASH. International Journal of Endocrinology, 2025(1). https://doi.org/10.1155/ije/6430023

Vancouver

Mousa AM, Mahmoud M, AlShuraiaan GM. Resmetirom: The First Disease‐Specific Treatment for MASH. International Journal of Endocrinology. 2025;2025(1). doi:10.1155/ije/6430023

BibTeX
@article{Mousa2025,
  author = {Mousa, Ali Mohamed and Mahmoud, Mervat and AlShuraiaan, Ghaida Mubarak},
  title = {Resmetirom: The First Disease‐Specific Treatment for MASH},
  journal = {International Journal of Endocrinology},
  year = {2025},
  volume = {2025},
  number = {1},
  doi = {10.1155/ije/6430023}
}
Kostenlos starten →